Tiziana Rancati
University of Milan
CancerInternal medicineRadiologyUrologySurgeryOncologyProspective cohort studyCohort studyProstateProstate cancerRectumPopulationToxicityNuclear medicineIn patientRadiation therapyBreast cancerMedicineCohortUrinary systemGastroenterology
306Publications
27H-index
2,540Citations
Publications 303
Newest
#1Irmgard HelmboldH-Index: 12
#2Petra SeiboldH-Index: 27
Last. F. WenzH-Index: 20
view all 16 authors...
#2Tiziana RancatiH-Index: 27
Last. Cesare CozzariniH-Index: 43
view all 25 authors...
Source
Source
Source
Source
#1Cesare CozzariniH-Index: 43
#2Tiziana RancatiH-Index: 27
Last. Claudio FiorinoH-Index: 54
view all 14 authors...
Abstract Background and purpose Urinary incontinence following radiotherapy (RT) for prostate cancer (PCa) has a relevant impact on patient’s quality of life. The aim of the study was to assess the unknown dose–effect relationship for late patient-reported urinary incontinence (LPRUI). Methods and materials Patients were enrolled within the multi-centric study DUE01. Clinical and dosimetry data including the prescribed 2 Gy equivalent dose (EQD2) were prospectively collected. LPRUI was evaluated...
12 CitationsSource
Source
Source
#1Carla SiniH-Index: 9
Last. Cesare CozzariniH-Index: 43
view all 19 authors...
Abstract Background and purpose Intestinal toxicity is commonly experienced during whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. The aim of the current study was to assess bowel dose–volume relationships for acute patient-reported intestinal symptoms of patients treated with WPRT for prostate cancer. Materials and methods Complete data of 206 patients were available; the median dose to pelvic nodes was 51.8 Gy (range 50.4–54.4, 1.7–2 Gy/fr). Intestinal symptoms were a...
13 CitationsSource
#1Tiziana RancatiH-Index: 27
#2Federica PaloriniH-Index: 11
Last. Riccardo Valdagni (University of Milan)H-Index: 51
view all 5 authors...
One of the most relevant achievements of Professor Gianni Bonadonna was the implementation of the methodology of controlled clinical trials in medical oncology. It is valid for all cancer types, on...
8 CitationsSource